| . | No bromocriptine (n = 467) . | Bromocriptine (n = 85) . | P-value . | n . |
|---|---|---|---|---|
| NYHA functional class at 6 months | .830 | 552 | ||
| I | 265 (60.6) | 50 (63.3) | 516 | |
| II | 153 (35.0) | 27 (34.2) | ||
| III | 16 (3.7) | 2 (2.5) | ||
| IV | 3 (0.7) | 0 (0.0) | ||
| Systolic BP (mmHg) at 6 months | 110.0 (100.0–120.0) | 110.0 (104.0–120.0) | .700 | |
| Diastolic BP (mmHg) at 6 months | 70.0 (65.0–80.0) | 73.0 (70.0–80.0) | .062 | 503 |
| Heart rate (b.p.m.) at 6 months | 76.0 (65.0–84.0) | 78.0 (70.0–84.0) | .180 | 503 |
| LVEDD (mm) at 6 months | 54.0 (48.0–60.0) | 55.0 (50.0–58.5) | .660 | 504 |
| LVESD (mm) at 6 months | 41.5 (35.0–50.0) | 40.0 (33.0–46.0) | .140 | 435 |
| LVEF (%) at 6 months | 48.0 (36.0–56.0) | 47.0 (42.0–55.5) | .570 | 381 |
| LVEF categories at 6 months | .031 | 467 | ||
| ≤35% | 95 (24.5) | 12 (15.0) | ||
| 36%–49% | 111 (28.7) | 34 (42.5) | ||
| ≥50% | 181 (46.8) | 34 (42.5) | ||
| Any thromboembolism | 26 (5.6) | 5 (6.0) | .900 | 547 |
| Venous thromboembolism | 18 (3.9) | 3 (3.6) | .890 | 547 |
| Arterial thromboembolism | 10 (2.2) | 2 (2.4) | .910 | 548 |
| Ischaemic stroke | 5 (1.1) | 2 (2.4) | .340 | 549 |
| Haemorrhagic stroke | 2 (0.4) | 0 (0.0) | .540 | 550 |
| Any stroke | 7 (1.5) | 2 (2.4) | .570 | 549 |
| Death within 6 months | 12 (2.6) | 2 (2.4) | .910 | 552 |
| Readmission within 6 months | 49 (10.5) | 8 (9.4) | .750 | 550 |
| Severe LV dysfunction at 6 months | 95 (24.6) | 12 (15.0) | .064 | 467 |
| Severe LV dysfunction or death at 6 months | 107 (26.8) | 14 (17.1) | .064 | 481 |
| Adverse maternal outcome at 6 months | 136 (33.3) | 18 (22.0) | .044 | 491 |
| . | No bromocriptine (n = 467) . | Bromocriptine (n = 85) . | P-value . | n . |
|---|---|---|---|---|
| NYHA functional class at 6 months | .830 | 552 | ||
| I | 265 (60.6) | 50 (63.3) | 516 | |
| II | 153 (35.0) | 27 (34.2) | ||
| III | 16 (3.7) | 2 (2.5) | ||
| IV | 3 (0.7) | 0 (0.0) | ||
| Systolic BP (mmHg) at 6 months | 110.0 (100.0–120.0) | 110.0 (104.0–120.0) | .700 | |
| Diastolic BP (mmHg) at 6 months | 70.0 (65.0–80.0) | 73.0 (70.0–80.0) | .062 | 503 |
| Heart rate (b.p.m.) at 6 months | 76.0 (65.0–84.0) | 78.0 (70.0–84.0) | .180 | 503 |
| LVEDD (mm) at 6 months | 54.0 (48.0–60.0) | 55.0 (50.0–58.5) | .660 | 504 |
| LVESD (mm) at 6 months | 41.5 (35.0–50.0) | 40.0 (33.0–46.0) | .140 | 435 |
| LVEF (%) at 6 months | 48.0 (36.0–56.0) | 47.0 (42.0–55.5) | .570 | 381 |
| LVEF categories at 6 months | .031 | 467 | ||
| ≤35% | 95 (24.5) | 12 (15.0) | ||
| 36%–49% | 111 (28.7) | 34 (42.5) | ||
| ≥50% | 181 (46.8) | 34 (42.5) | ||
| Any thromboembolism | 26 (5.6) | 5 (6.0) | .900 | 547 |
| Venous thromboembolism | 18 (3.9) | 3 (3.6) | .890 | 547 |
| Arterial thromboembolism | 10 (2.2) | 2 (2.4) | .910 | 548 |
| Ischaemic stroke | 5 (1.1) | 2 (2.4) | .340 | 549 |
| Haemorrhagic stroke | 2 (0.4) | 0 (0.0) | .540 | 550 |
| Any stroke | 7 (1.5) | 2 (2.4) | .570 | 549 |
| Death within 6 months | 12 (2.6) | 2 (2.4) | .910 | 552 |
| Readmission within 6 months | 49 (10.5) | 8 (9.4) | .750 | 550 |
| Severe LV dysfunction at 6 months | 95 (24.6) | 12 (15.0) | .064 | 467 |
| Severe LV dysfunction or death at 6 months | 107 (26.8) | 14 (17.1) | .064 | 481 |
| Adverse maternal outcome at 6 months | 136 (33.3) | 18 (22.0) | .044 | 491 |
BP, blood pressure; LVH, left ventricular hypertrophy; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
| . | No bromocriptine (n = 467) . | Bromocriptine (n = 85) . | P-value . | n . |
|---|---|---|---|---|
| NYHA functional class at 6 months | .830 | 552 | ||
| I | 265 (60.6) | 50 (63.3) | 516 | |
| II | 153 (35.0) | 27 (34.2) | ||
| III | 16 (3.7) | 2 (2.5) | ||
| IV | 3 (0.7) | 0 (0.0) | ||
| Systolic BP (mmHg) at 6 months | 110.0 (100.0–120.0) | 110.0 (104.0–120.0) | .700 | |
| Diastolic BP (mmHg) at 6 months | 70.0 (65.0–80.0) | 73.0 (70.0–80.0) | .062 | 503 |
| Heart rate (b.p.m.) at 6 months | 76.0 (65.0–84.0) | 78.0 (70.0–84.0) | .180 | 503 |
| LVEDD (mm) at 6 months | 54.0 (48.0–60.0) | 55.0 (50.0–58.5) | .660 | 504 |
| LVESD (mm) at 6 months | 41.5 (35.0–50.0) | 40.0 (33.0–46.0) | .140 | 435 |
| LVEF (%) at 6 months | 48.0 (36.0–56.0) | 47.0 (42.0–55.5) | .570 | 381 |
| LVEF categories at 6 months | .031 | 467 | ||
| ≤35% | 95 (24.5) | 12 (15.0) | ||
| 36%–49% | 111 (28.7) | 34 (42.5) | ||
| ≥50% | 181 (46.8) | 34 (42.5) | ||
| Any thromboembolism | 26 (5.6) | 5 (6.0) | .900 | 547 |
| Venous thromboembolism | 18 (3.9) | 3 (3.6) | .890 | 547 |
| Arterial thromboembolism | 10 (2.2) | 2 (2.4) | .910 | 548 |
| Ischaemic stroke | 5 (1.1) | 2 (2.4) | .340 | 549 |
| Haemorrhagic stroke | 2 (0.4) | 0 (0.0) | .540 | 550 |
| Any stroke | 7 (1.5) | 2 (2.4) | .570 | 549 |
| Death within 6 months | 12 (2.6) | 2 (2.4) | .910 | 552 |
| Readmission within 6 months | 49 (10.5) | 8 (9.4) | .750 | 550 |
| Severe LV dysfunction at 6 months | 95 (24.6) | 12 (15.0) | .064 | 467 |
| Severe LV dysfunction or death at 6 months | 107 (26.8) | 14 (17.1) | .064 | 481 |
| Adverse maternal outcome at 6 months | 136 (33.3) | 18 (22.0) | .044 | 491 |
| . | No bromocriptine (n = 467) . | Bromocriptine (n = 85) . | P-value . | n . |
|---|---|---|---|---|
| NYHA functional class at 6 months | .830 | 552 | ||
| I | 265 (60.6) | 50 (63.3) | 516 | |
| II | 153 (35.0) | 27 (34.2) | ||
| III | 16 (3.7) | 2 (2.5) | ||
| IV | 3 (0.7) | 0 (0.0) | ||
| Systolic BP (mmHg) at 6 months | 110.0 (100.0–120.0) | 110.0 (104.0–120.0) | .700 | |
| Diastolic BP (mmHg) at 6 months | 70.0 (65.0–80.0) | 73.0 (70.0–80.0) | .062 | 503 |
| Heart rate (b.p.m.) at 6 months | 76.0 (65.0–84.0) | 78.0 (70.0–84.0) | .180 | 503 |
| LVEDD (mm) at 6 months | 54.0 (48.0–60.0) | 55.0 (50.0–58.5) | .660 | 504 |
| LVESD (mm) at 6 months | 41.5 (35.0–50.0) | 40.0 (33.0–46.0) | .140 | 435 |
| LVEF (%) at 6 months | 48.0 (36.0–56.0) | 47.0 (42.0–55.5) | .570 | 381 |
| LVEF categories at 6 months | .031 | 467 | ||
| ≤35% | 95 (24.5) | 12 (15.0) | ||
| 36%–49% | 111 (28.7) | 34 (42.5) | ||
| ≥50% | 181 (46.8) | 34 (42.5) | ||
| Any thromboembolism | 26 (5.6) | 5 (6.0) | .900 | 547 |
| Venous thromboembolism | 18 (3.9) | 3 (3.6) | .890 | 547 |
| Arterial thromboembolism | 10 (2.2) | 2 (2.4) | .910 | 548 |
| Ischaemic stroke | 5 (1.1) | 2 (2.4) | .340 | 549 |
| Haemorrhagic stroke | 2 (0.4) | 0 (0.0) | .540 | 550 |
| Any stroke | 7 (1.5) | 2 (2.4) | .570 | 549 |
| Death within 6 months | 12 (2.6) | 2 (2.4) | .910 | 552 |
| Readmission within 6 months | 49 (10.5) | 8 (9.4) | .750 | 550 |
| Severe LV dysfunction at 6 months | 95 (24.6) | 12 (15.0) | .064 | 467 |
| Severe LV dysfunction or death at 6 months | 107 (26.8) | 14 (17.1) | .064 | 481 |
| Adverse maternal outcome at 6 months | 136 (33.3) | 18 (22.0) | .044 | 491 |
BP, blood pressure; LVH, left ventricular hypertrophy; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
